Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature

Authors Daniel J Abrams, Donald C Rojas, David B Arciniegas

Published Date November 2008 Volume 2008:4(6) Pages 1089—1109

DOI http://dx.doi.org/10.2147/NDT.S4120

Published 27 November 2008

Daniel J Abrams1, Donald C Rojas1, David B Arciniegas1,2

1Department of Psychiatry; 2Neurobehavioral Disorders Program, Departments of Psychiatry and Neurology, University of Colorado School of Medicine, Denver, CO, USA

Abstract: Considerable debate surrounds the inclusion of schizoaffective disorder in psychiatric nosology. Schizoaffective disorder may be a variant of schizophrenia in which mood symptoms are unusually prominent but not unusual in type. This condition may instead reflect a severe form of either major depressive or bipolar disorder in which episode-related psychotic symptoms fail to remit completely between mood episodes. Alternatively, schizoaffective disorder may reflect the co-occurrence of two relatively common psychiatric illnesses, schizophrenia and a mood disorder (major depressive or bipolar disorder). Each of these formulations of schizoaffective disorder presents nosological challenges because the signs and symptoms of this condition cross conventional categorical diagnostic boundaries between psychotic disorders and mood disorders. The study, evaluation, and treatment of persons presently diagnosed with schizoaffective may be more usefully informed by a dimensional approach. It is in this context that this article reviews and contrasts the categorical and dimensional approaches to its description, neurobiology, and treatment. Based on this review, an argument for the study and treatment of this condition using a dimensional approach is offered.

Keywords: schizoaffective disorder, schizophrenia, bipolar disorder, manic-depressive disorder

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Rationale, design, and cohort enrolment of a prospective observational study of the clinical performance of the new contraceptive implant (Femplant) in Pakistan

Azmat SK, Hameed W, Lendvay A, Shaikh BT, Mustafa G, Siddiqui MA, Brohi S, Karim A, Ishaque M, Hussain W, Bilgrami M, Feldblum PJ

International Journal of Women's Health 2014, 6:573-583

Published Date: 29 May 2014

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:1363-1364

Published Date: 4 July 2013

Cytoprotective and enhanced anti-inflammatory activities of liposomal piroxicam formulation in lipopolysaccharide-stimulated RAW 264.7 macrophages

Chiong HS, Yong YK, Ahmad Z, Sulaiman MR, Zakaria ZA, Yuen KH, Hakim MN

International Journal of Nanomedicine 2013, 8:1245-1255

Published Date: 22 March 2013

Astigmatism induced by conventional spherical ablation after PRK and LASIK in myopia with astigmatism < 1.00 D

Christiansen SM, Mifflin MD, Edmonds JN, Simpson RG, Moshirfar M

Clinical Ophthalmology 2012, 6:2109-2117

Published Date: 20 December 2012

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)

Paolo Solla, Antonino Cannas, Francesco Marrosu, et al

Neuropsychiatric Disease and Treatment 2010, 6:483-490

Published Date: 4 August 2010

In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection

Torben Gjetting, Nicolai Skovbjerg Arildsen, Camilla Laulund, et al

International Journal of Nanomedicine 2010, 5:371-383

Published Date: 25 May 2010

Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer’s disease

Tiffany W Chow, Bruce G Pollock, Norton W Milgram

Neuropsychiatric Disease and Treatment 2007, 3:627-636

Published Date: 29 November 2007

A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis

Mark Abelson, Eugene Protzko, Aron Shapiro, Ana Garces-Soldana, Lyle Bowman, 1% azithromycin in DuraSite Clinical Study Group

Clinical Ophthalmology 2007, 1:177-182

Published Date: 5 October 2007